St. Jude Medical Announces U.S. Clearance for Cardiac Image Integration Software

ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration (FDA) clearance for its EnSite Fusion™ Registration Module. The new software will help physicians create detailed heart models to facilitate the diagnosis and delivery of therapy for complex abnormal atrial heart rhythms, including Atrial Fibrillation (AF).
MORE ON THIS TOPIC